Zur Sprachwahl
Zur Metanavigation
Zur Sucheingabe
Zur den Bannertabs
Zur Hauptnavigation
Zum Inhalt
Mobile Header

    Artificial skin with the help of 3D bioprinting

    7/27/15 | 8:07 AM time

    BASF and Poietis signed a research and development agreement for skin care applications with the aid of 3D bioprinting technology

    The German chemicals group BASF and the French start-up company Poietis announced a research and development agreement in cosmetics. According to both companies, Poietis will support the further development of the skin equivalent model Mimeskin™ by BASF in the future.

    Poietis is by its own account the first company in the world for 3D laser-assisted bioprinting and specialises in the reproduction of organic tissues. By using 3D bioprinting technology, an even more precise positioning of the skin cells in three-dimensional structures is made possible – in so doing, cells are cultivated within BASF’s skin model Mimeskin™.

    3D bioprinting allows for a quicker and more precise production of the skin model Mimeskin™

    The aim of the agreement is to establish an automated reproduction of Mimeskin™, which would shorten the production process significantly, BASF states. The research and development of further more advanced skin models with additional cell types is also part of the cooperation contract.

    “Compared to other bioprinting methods the laser-assisted technology provides higher resolution when it comes to the patterning of cells. The partnership with Poietis allows BASF to secure its strategic advantage in better understanding the skin mechanisms which support the development and testing of advanced cosmetic bioactives for skin care applications,” remarks Dr. Sebastien Cadau, responsible for tissue engineering development at BASF.

    The cooperation between BASF and Poietis is also in hopes of establishing an alternative to animal testing in cosmetics and dermopharmacy.

    L’Oréal: “The potential is boundless”

    The French cosmetics group L’Oréal also recently signed an agreement with 3D bioprinting company Organavo to further optimise the development and testing of cosmetic ingredients. The 3D technology will be used within the patented skin model Episkin by L’Oréal.

    “Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless," Guive Balooch, Global Vice President of L’Oréal’s Technology Incubator, points out. 

    Sources: BASF, Poietis, L’Oréal

    Picture: 2015 © Ludovc Lescieux (Alphanov) / Fabien Guillemot (INSERM – Poietis)

    Article & Editorial Archive

    Please type in your search term.

    Imprint| Data protection © Leipziger Messe 2021. All rights reserved.